2022 Conference Agenda

Day One - May 23, 2022

7:55 am

Chairperson's Opening Remarks

Charles Nichols, Ph.D., Professor, Pharmacology & Experimental Therapeutics LSU Health Sciences Center

8:00 am

FDA Study Participants & National Patient Advocacy

In this session, our speakers will discuss their first-hand experience in FDA psychedelic clinical trials. They will also discuss advocacy for federal approval, the legislative roadmap, how to bridge university research, patient advocacies, nonprofits, and for-profits to make this treatment both accessible and affordable. The missing piece and most impactful voices of this research are of the study participants. They know the potential of these therapies which can help solve the mental health crisis and save the nation billions of dollars from ineffective treatments and lost productivity in the workforce.
Jon Kostakopoulos, President & CEO, Apollo Pact
Ali Amirhooshmand, Chief Operating Officer, Apollo Pact
Jonathan Lubecky, US Army SGT (Retired), Veterans & Governmental Affairs Liaison, MAPS (Multidisciplinary Association for Psychedelic Studies), Vice President Communications & Veterans Affairs, Apollo Pact

8:30 am

From NHL Enforcer to CEO: Leading the Charge to Healing TBI

Daniel Carcillo, known for winning two Stanley Cups with the Chicago Blackhawks and his advocacy for TBI, is passionate about improving the way we heal the brain. In this talk Daniel will share his journey, from NHL Enforcer to CEO of a psychedelic company. After taking hits to the head from the age of 4 on, Daniel Carcillo began having symptoms of conditions associated with traumatic brain injury. By the time he was in his late 20s, he was beginning to think of ending his life in order to end his own suffering and that of the people who loved him. After a transformational experience with psychedelic medicines, and the scientific evidence to back the return to normalcy he was feeling, Daniel began to see a path to bring help to others. It was from this experience that Wesana was born.
Daniel Carcillo, Chief Executive Officer/Founder, Wesana Health

8:55 am

Regulatory Submissions and Beyond: Designing Psychedelic Research to Advance Product Candidates and Inform the Field

Robert Barrow, Chief Executive Officer, MindMed

9:20 am

Last Mile Challenge of Psychedelic Drug Therapy

Shlomi Raz, Chief Executive Officer, Eleusis

9:45 am

Government-approved at Home Microdosing Clinical Trials and Changing the Course of Mental Health Treatment

Justin Hanka, Co-Founder, MindBio Therapeutics

10:10 am

Morning Break

Visit the scientific poster session, network with colleagues over coffee and snacks, visit with our exhibitors and meet new people via our meeting scheduling solution.

10:35 am

Leveling Up to Psychedelic 2.0: Solving the Problems Presented by Medical Use of Psychedelics

In this presentation, Dr. Becker will discuss how Bexson Biomedical is seeking to solve the serious pharmacokinetic problems presented by medical use of ketamine and psychedelics through its dual platform technologies that combine subcutaneous formulations with dose metered delivery devices. Their approach aims to solve problems presented in graduating these important treatments to medical settings, including: controlling medical office timeframes & clinical on/off windows; reducing nausea, vomiting & malaise medicated by GI serotonin receptors; decreasing metabolite exposure & cardiac risk; establishing inter-patient & intra-patient treatment consistency; permitting rapid dosing attunement during treatment; establishing tamper resistance & diversion control; dispensing with IV procedural burden & cost; and Improving parameters of set & setting.
Jeffrey Becker, MD, Chief Scientific Officer, Bexson Biomedical

11:00 am

The Durability of Psilocybin Therapy for the Treatment of Mood Disorders

In this presentation Dr. Barrett will review recent evidence for the efficacy of psilocybin therapy for the treatment of symptoms of depression and anxiety. He will focus on the durability of this response, especially in a recent clinical trial showing that nearly 78% of patients had a clinically significant response (≥50% reduction in depression severity from basline), and over 50% were in remission, at 12 months after treatment.
Frederick Barrett, Ph.D., Associate Professor of Psychiatry & Behavioral Sciences, Johns Hopkins School of Medicine

11:30 am

Human Trials in Psychedelics: Implications and Considerations in the Clinical Trial Process

This talk seeks to share knowledgeable insights and recommendations about study design, recruitment strategies, ethical and cultural considerations and study management. As momentum and appetite grow for psychedelic treatments and clinical trials, Ms. Grewal will also provide brief regulatory and study updates from the sector and share lessons learned from early clinical trials.
Jaspreet Grewal, Chief Executive Officer & Co-Founder, Knowde Group
Sabrina Ramkellawan, Chief Operating Officer & Co-Founder, Knowde Group, Board of Directors, MAPS Canada, President, Clinical Research Association of Canada

12:00 pm

The Molecular, Genetic, and Behavioral Effects of Psychedelics in Rat Experimental Systems to Study Psychiatric Disorders

We have been investigating cellular, molecular, and genetic aspects of psychedelic drug action in rat brain, and have developed rat experimental systems that recapitulate the long lasting antidepressant effects observed in humans.  In these systems, a single treatment with drug has persistent antidepressant-like effects lasting at full effect for at at least several weeks to months. In this presentation, the effects of psychedelics in the CNS at the molecular, genetic, and behavioral level relevant to therapeutic effects will be presented.
Charles Nichols, Ph.D., Professor, Pharmacology & Experimental Therapeutics, LSU Health Sciences Center

12:30 pm

Lunch Break

We have numerous options for your lunch experience. Join colleagues in our dedicated lunch space, eat in the restaurant, eat outside on the restaurant patio, or take a box lunch and retire to your guest room for some quiet time.

1:30 pm

The Importance of Next Generation Psychedelic Drugs in Treating Mental Health Afflictions

James Lanthier, Chief Executive Officer, Mindset Pharma

1:55 pm

Molecular Target and Mechanisms of Psychedelic-induced Plasticity

Clinical evidence suggests a potential therapeutic effect of classic psychedelics for the treatment of psychiatric conditions such as depression and substance use disorder. This talk will review our recent preclinical findings related to the molecular target and neural circuit involved in the acute and post-acute effects of psychedelics on processes that include frontal cortex dendritic spine structure, receptor density, and animal models of opioid use disorder.
Javier Gonzalez Maeso, Ph.D., Professor, Department of Physiology & Biophysics Virginia Commonwealth University

2:25 pm

Real World and Clinical Trial Data Supporting Classic Psychedelics as Emerging Treatments for Substance Use Disorders

Peter Hendricks, Ph.D., Professor of Public Health, University of Alabama Birmingham

2:55 pm

Afternoon Break

Visit the scientific poster session, network with colleagues over coffee and snacks, visit with our exhibitors and meet new people via our meeting scheduling solution.

3:20 pm

Beyond Psychedelics: Venturing into a New Era of Serotonergic Drug Discovery

In this presentation, Dr. McCorvy will outline several strategies to design and develop selective or promiscuous serotonin receptor drugs. Many of these novel compounds show preferences for serotonin receptor signaling pathways known as functionally selective or biased agonists. These compounds will have advantages over current psychedelics for a plethora of potential therapeutic indications and open up questions toward more informed drug design for depression and psychosis.
John McCorvy, Ph.D., Assistant Professor, Cell Biology, Neurobiology & Anatomy, Medical College of Wisconsin

3:50 pm

PANEL SESSION: Clinical Trials of Psychedelics: Challenges and Opportunities

Chair: Eric Strain, MD, Professor; Director, Johns Hopkins Center for Substance Abuse Treatment and Research, Johns Hopkins University

Research Designs and Methods

Robert H. Dworkin, Ph.D., Professor of Anesthesiology and Perioperative Medicine, Neurology, and Psychiatry, University of Rochester School of Medicine and Dentistry

Biomarker Potential of fMRI

Ted Satterthwaite, MD, Associate Professor of Psychiatry, Director, Penn Lifespan Informatics & Neuroimaging Center, University of Pennsylvania, Perelman School of Medicine

Safety Considerations in Psychedelic Clinical Trials
Charles Grob, MD
, Professor of Psychiatry & Biobehavioral Sciences and Pediatrics, David Geffen School of Medicine; Investigator, University of California Los Angeles; The Lundquist Institute

5:20 pm

Reception: Hors d'oeuvres & Drinks

About Us

Arrowhead Conferences offer an experience that encompasses learning, networking and professional growth. We focus on bringing life sciences industry professionals together to help move research forward.


Contact Details

+1 866-945-0263


Organized By